UPDATE: Oppenheimer Downgrades Rocket Pharmaceuticals (RCKT) to Perform

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. ANT
3. SPY
4. FFAI
5. FFR
6. CART
7. LLY
8. TSLA
9. META
10. FICO

Go back to UPDATE: Oppenheimer Downgrades Rocket Pharmaceuticals (RCKT) to Perform

Rocket Pharmaceuticals Presents Positive Clinical Data from its Fanconi Anemia and Leukocyte Adhesion Deficiency-I Programs at the 62nd American Society of Hematology Annual Meeting

December 7, 2020 2:30 PM EST

Two of Three FA Process B Patients with at Least 12-Months Follow-Up and Three of Four Additional Patients with Shorter Follow-Up Demonstrate Evidence of Engraftment

Follow-Up Data from Phase 1/2 Trial for Leukocyte Adhesion Deficiency-I Demonstrate Durable CD18 Expression

Both Trials on Track and Continue to Support Potential Registration Path Using Process B

NEW YORK--(BUSINESS... More

Rocket Pharmaceuticals Announces Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency at the 62nd American Society of Hematology Annual Meet

December 6, 2020 10:00 AM EST

Preliminary Data from First Patient Demonstrates Initial Safety and Tolerability of RP-L301, Near Doubling of Hemoglobin to Normal Range and Additional Normalization of Hemolysis Markers

Rockets Largest Lentiviral Pipeline Program Aims to Address Unmet Need for up to 8,000 PKD Patients in the U.S. and Europe

NEW YORK--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ:... More